These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32849281)

  • 1. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
    Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
    Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
    Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
    [No Abstract]   [Full Text] [Related]  

  • 4. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
    Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
    J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
    Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
    Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 9. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
    Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?
    Fonseca L; Freitas C; Caramelo A; Eloy C
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00241. PubMed ID: 34277966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
    Cano JM; Galán R; López R
    Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual Presentation of Metastatic Medullary Thyroid Cancer Involving Bone Marrow, Kidneys, and Adrenal Gland: A Literature Review Based on a Case Report.
    Ebrahimi P; Payab M; Shariati A; Alipour N; Nozheh A; Tavangar SM; Taheri H; Ebrahimpur M
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e70022. PubMed ID: 39410877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
    Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
    Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
    Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
    Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression in Medullary Thyroid Carcinoma and Its Association with Clinicopathological Findings.
    Kemal Y; Çalişkan S; Gun S; Kefeli M
    Turk Patoloji Derg; 2022; 38(2):106-113. PubMed ID: 34580845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.